GeneDx Net Income From Continuing Ops from 2010 to 2025

WGSWW Stock   0.21  0.01  4.32%   
GeneDx Holdings Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to about -166.1 M in 2025. During the period from 2010 to 2025, GeneDx Holdings Net Loss regression line of quarterly data had mean square error of 13296.1 T and geometric mean of  64,053,431. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-158.2 M
Current Value
-166.1 M
Quarterly Volatility
141.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check GeneDx Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GeneDx Holdings' main balance sheet or income statement drivers, such as Net Interest Income of 1.3 M, Interest Income of 3.1 M or Depreciation And Amortization of 31.3 M, as well as many indicators such as Price To Sales Ratio of 0.36, Dividend Yield of 0.0 or PTB Ratio of 0.52. GeneDx financial statements analysis is a perfect complement when working with GeneDx Holdings Valuation or Volatility modules.
  
Check out the analysis of GeneDx Holdings Correlation against competitors.

Latest GeneDx Holdings' Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of GeneDx Holdings Corp over the last few years. It is GeneDx Holdings' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GeneDx Holdings' overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

GeneDx Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(114,550,445)
Geometric Mean64,053,431
Coefficient Of Variation(123.91)
Mean Deviation106,058,056
Median(29,704,000)
Standard Deviation141,944,133
Sample Variance20148.1T
Range519.3M
R-Value(0.62)
Mean Square Error13296.1T
R-Squared0.38
Significance0.01
Slope(18,477,085)
Total Sum of Squares302222.1T

GeneDx Net Income From Continuing Ops History

2025-166.1 M
2024-158.2 M
2023-175.8 M
2022-549 M
2021-245.4 M
2020-241.3 M

About GeneDx Holdings Financial Statements

GeneDx Holdings investors use historical fundamental indicators, such as GeneDx Holdings' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in GeneDx Holdings. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-158.2 M-166.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for GeneDx Stock Analysis

When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.